Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2026Blood

Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study

View Full Paper
Ask AI
Bookmark
Share

Authors

RORobert Z. OrlowskiThe University of Texas MD Anderson Cancer CenterMDMeletios A. DimopoulosKorea UniversityXLXavier LeleuInserm

Discussion

Loading...

Member takes

Implication

Randomized Phase 3 trial demonstrates improved MRD-negativity in newly diagnosed multiple myeloma, suggesting enhanced treatment efficacy.

Key Points

  • To analyze the dynamics of minimal residual disease (MRD) negativity in newly diagnosed multiple myeloma patients treated with isa-vrd.
  • Conducted a randomized Phase 3 trial (IMROZ) comparing isa-vrd treatment to vr-d treatment.
  • Evaluated MRD status and clinical outcomes over a follow-up of 60 months.
  • Analyzed patient subgroups including older and frail patients.
  • Patients receiving isa-vrd showed higher rates of MRD-negativity compared to vr-d at various timepoints.
  • Significant prolongation in time-to-progression for patients converting from MRD-positive to MRD-negative on isa-vrd.
  • Improved clinical outcomes were observed with isa-vrd across key patient subgroups.

Cite This Study

Orlowski et al. (2026) studied this question.

synapsesocial.com/papers/69a3d7dfec16d51705d2e34fhttps://doi.org/10.1182/blood.2025030120
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).2024 · 6 citations
  2. 2Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).2024 · 3 citations
  3. 3Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial2024 · 119 citations
  4. 4Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)2025 · 1 citations
  5. 5P15 | RANDOMIZED COMPARISON OF ISATUXIMAB–RD INDUCTION FOLLOWED BY ISA R MAINTENANCE VS. RD INDUCTION FOLLOWED BY R MAINTENANCE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (AGMT MM04 TRIAL)2026